News
Public · Published
Boston Scientific (NYSE:BSX) posts better-than-expected sales in Q3 2026 but quarterly revenue guidance misses expectations
Boston Scientific reported Q3 2026 revenue of $5.14 billion, up 1.4% year on year and above analysts' consensus estimate of $5.07 billion. Its Q4 2026 revenue guidance midpoint of $5.18 billion came in 4.5% below analysts' consensus estimates.
Published:
Updated:
What happened
Boston Scientific reported Q3 2026 revenue of $5.14 billion, up 1.4% year on year and above analysts' consensus estimate of $5.07 billion. Its Q4 2026 revenue guidance midpoint of $5.18 billion came in 4.5% below analysts' consensus estimates.
Confirmed
Global impact / market context
The quarterly beat shows demand held up, but the weak next-quarter sales guidance suggests growth may slow ahead. Because Boston Scientific also lowered its full-year adjusted profit guidance, investors could question whether the company's sales outlook supports its earnings.
Analyst inference
Boston Scientific said it managed a cybersecurity incident this year, which means an event affecting its computer systems. Its operating profit per sale fell to 16.1% from 20.7% a year earlier, a sign that costs are taking a larger share of revenue.
Analyst inference
What to watch
- Watch whether Boston Scientific's Q4 2026 revenue lands near its $5.18 billion guidance midpoint or closer to analysts' higher consensus estimate. Confirmed
- Management could face questions about restoring operations after the cybersecurity incident and whether related costs or disruptions keep weighing on sales and operating profit per sale. Proposed
- Investors may compare the lowered full-year adjusted profit guidance of $3.17 with the Q4 revenue outlook to judge whether cost pressures are easing or persist. Analyst inference